AGBL3 and B-cell chronic lymphocytic leukemia: Elevated levels of anti-CCP3 were also associated with a reduced risk of CLL (Ptrend = 5 × 10−4, Fig. 1b) with the highest quintile of anti-CCP3 showing a 56% reduced CLL risk compared to the lowest quintile (OR5th vs. 1st quintile = 0.44, 95% CI: 0.26–0.74, P = 0.002).